Challenges in neoantigen-directed therapeutics
L Lybaert, S Lefever, B Fant, E Smits, B De Geest… - Cancer Cell, 2023 - cell.com
A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …
[HTML][HTML] Biomarker discovery and application—an opportunity to resolve the challenge of liver cancer diagnosis and treatment
J Chen, C Niu, N Yang, C Liu, S Zou, S Zhu - Pharmacological Research, 2023 - Elsevier
Liver cancer is one of the most common malignancies, with severe morbidity and mortality.
While considerable progress has been made in liver cancer treatment, the 5-year overall …
While considerable progress has been made in liver cancer treatment, the 5-year overall …
TLimmuno2: predicting MHC class II antigen immunogenicity through transfer learning
Major histocompatibility complex (MHC) class II molecules play a pivotal role in antigen
presentation and CD4+ T cell response. Accurate prediction of the immunogenicity of MHC …
presentation and CD4+ T cell response. Accurate prediction of the immunogenicity of MHC …
Benchmark of tools for in silico prediction of MHC class I and class II genotypes from NGS data
A Claeys, P Merseburger, J Staut, K Marchal… - BMC genomics, 2023 - Springer
Abstract Background The Human Leukocyte Antigen (HLA) genes are a group of highly
polymorphic genes that are located in the Major Histocompatibility Complex (MHC) region …
polymorphic genes that are located in the Major Histocompatibility Complex (MHC) region …
Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity
Human leukocyte antigen class I (HLA-I) genes shape our immune response against
pathogens and cancer. Certain HLA-I variants can bind a wider range of peptides than …
pathogens and cancer. Certain HLA-I variants can bind a wider range of peptides than …
RBM10 deficiency is associated with increased immune activity in lung adenocarcinoma
B Liu, Y Wang, H Wang, Z Li, L Yang, S Yan… - Frontiers in …, 2021 - frontiersin.org
Introduction RBM10 is one of the frequently mutated genes in lung adenocarcinoma (LUAD).
Previous studies have confirmed that RBM10 could suppress the disease progression and …
Previous studies have confirmed that RBM10 could suppress the disease progression and …
In silico pipeline to identify tumor-specific antigens for cancer immunotherapy using exome sequencing data
D Morazán-Fernández, J Mora, JA Molina-Mora - Phenomics, 2023 - Springer
Tumor-specific antigens or neoantigens are peptides that are expressed only in cancer cells
and not in healthy cells. Some of these molecules can induce an immune response, and …
and not in healthy cells. Some of these molecules can induce an immune response, and …
Human leucocyte antigens as prognostic markers in head and neck squamous cell carcinoma
G Dyckhoff, C Herold-Mende, S Scherer, PK Plinkert… - Cancers, 2022 - mdpi.com
Simple Summary Human leucocyte antigens (HLAs) play a crucial role in the immune
defense by presenting antigens to T lymphocytes. The particular combination of HLA alleles …
defense by presenting antigens to T lymphocytes. The particular combination of HLA alleles …
[HTML][HTML] Historical perspective and future directions: computational science in immuno-oncology
Immuno-oncology holds promise for transforming patient care having achieved durable
clinical response rates across a variety of advanced and metastatic cancers. Despite these …
clinical response rates across a variety of advanced and metastatic cancers. Despite these …
Quantification of neoantigen-mediated immunoediting in cancer evolution
Immunoediting includes three temporally distinct stages, termed elimination, equilibrium,
and escape, and has been proposed to explain the interactions between cancer cells and …
and escape, and has been proposed to explain the interactions between cancer cells and …